<DOC>
	<DOC>NCT00635219</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder (MDD).</brief_summary>
	<brief_title>Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>MDE as primary diagnosis according to DSMIVTR criteria (classification code 296.xx) Moderate to severe depression Current MDE duration of at least 3 months Any current psychiatric disorder other than MDD as defined in the DSMIV TR Any substance disorder within the previous 6 months Female patients of childbearing potential who are not using effective contraception Use of any psychoactive medication 2 weeks prior to screening and during the study Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Active reference</keyword>
	<keyword>Multicenter study</keyword>
	<keyword>Randomised study</keyword>
	<keyword>Acute treatment</keyword>
</DOC>